IntegriMedical successfully showcased to the world, our Needle Free Injection System. We were thrilled with the amazing response to our Revolutionary product at MEDICA – Leading International Trade Fair, Dusseldorf 2022.
Empowered Patient Podcast: Scott McFarland, CEO, IntegriMedical has taken on the challenge of needle phobia and safe and secure disposal of sharp objects in clinics and in the field. Needle-free technology is allowing healthcare professionals to quickly administer vaccinations with a greener approach allowing regular biohazard disposal. Working with vaccine and biologic manufacturers this needle-free approach may be instrumental in the rapid deployment of a COVID-19 vaccine.
Our Director, Sarvesh Mutha being interviewed by a leading medical device news channel during Medical Fair Asia 2022
Medical Fair Asia 2022 was a momentous event for IntegriMedical. We introduced our ingenious product at the expo, showcasing our innovation and technological advancement in drug delivery solutions, parallel to none.
Bloomberg: DelveInsight launched a new report on ” Needle-Free Injections Market & Competitive Landscape ,” providing in-depth market understanding for Needle-Free Injections, which will further benefit the competitors or stakeholders operating in the Needle-Free Injections arena. Recent Developmental Activities in Needle-Free Injections Market * In August 2021, PharmaJet and their partner Zydus Cadila announced the emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world’s first Plasmid DNA Vaccine for COVID-19. The vaccine- ZyCoV-D is exclusively administered by deploying the PharmaJet Tropis® Needle-free Injection System. * In October 2020, PharmaJet’s Needleless vaccine injector was chosen to deliver one of the COVID-19 vaccines- the University of Cambridge’s phase 1 trial of DIOSynVax’s candidate. The trial will test the delivery of the vaccine through the skin without using needles. Interested in knowing how the Needle-Free Injections Market will be growing by 2026? Click to get a snapshot of Needle-Free Injections Market Analysis . Needle-Free Injections Overview Needle-free injection technology (NFIT) is a tremendously broad notion that comprises a wide range of drug delivery systems that delivers drugs through the skin by any of the forces such as Lorentz, Shock waves, pressure by gas or electrophoresis, which forces the drug through the skin, almost abolishing the use of a hypodermic needle. This is beneficial for the pharmaceutical industry, and developing countries find it extremely valuable in mass immunisation programs, avoiding the chances of needle stick injuries and other complications, including those arising due to multiple uses of a single needle. These devices can be categorised based on their working, type of load, mechanism of drug delivery and site of delivery. According to the World Health Organization (WHO) 2021, in 2019, the number of individuals affected with diabetes has increased drastically from 108 million in 1980 to 422 million in 2014. According to the data provided by the International Diabetes Federation (IDF) Diabetes Atlas Ninth Edition 2019, there were approximately 463 million adults in the age group 20-79 years and is expected to reach 700 million by 2045. Geography-Wise Needle-Free Injections Market Analysis Geographically, the global Needle-Free Injections market is studied for North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America is expected to account for the largest share in the needle-free injections market because of the high prevalence of chronic diseases, increase in the awareness regarding needle-free injections, improving disposable income, and better healthcare infrastructure along with the presence of major market players in the region among other factors in the region. One of the key factors supporting the growth of the Needle-Free Injections market in the region is the high prevalence of diabetes. According to the Centers for Disease Control and Prevention 2021, almost 34 million people in the United States have diabetes, with 90-95% of them having type 2 diabetes. Therefore, an increase in the prevalence rate of the diabetes suffering population will lead to a greater demand for Needle-Free Injections in the market, further elevating the market growth. Furthermore, the growing collaborations between the needle-free injection devices manufacturers and pharmaceutical companies in the region are further driving the needle-free injections market in the United States, and therefore in North America. To know more why North America is leading the market growth in the Needle-Free Injections market, get a snapshot of Needle-Free Injections market report There are great opportunities for Needle-Free Injections market penetration for countries like China, India, and Japan as the prevalence rate is high. According to the IDF Diabetes Atlas 9th Edition, an estimated 87.6 million adults aged 20-79 years were living with diabetes in the South-East Asia region in 2019, representing a regional prevalence of 8.8%. This is expected to increase to 153 million by 2045. It is estimated that around 60% of diabetics in the world live in Asia. Covid-19 Impact on Needle-Free Injections Market The demand for Needle-Free Injections is primarily affected by the outbreak of the COVID-19 pandemic because of the delay in the supply and manufacturing of the products. However, Type 2 diabetes, hypertension, and cardiovascular diseases have been identified as the most common comorbidities for SARS-CoV-2 infection and have been associated with worse outcomes and more severe courses of COVID-19. It was estimated that 10% of COVID-19 vaccine hesitancy maybe because of needle phobia, creating a demand for alternative delivery routes to clear a barrier to vaccination, such as Needle-Free Injections. The demand for Needle-Free Injections was boosted by the approval of vaccines like Zydus’ vaccine, which will be administered by needle-free injections in August 2021. In September 2021, Scancell advanced its effort to provide an alternative by tapping PharmaJet for needle-free delivery technologies. It is approved in South Africa to run a phase I clinical trial of the vaccine candidates in July, where the investigators will administer the vaccines using the PharmaJet Tropis and PharmaJet Stratis needle-free injection systems.
We are conducting essential training sessions regularly in prestigious hospitals across the world, as to transition in the revolutionary phase will require a certain amount of hand holding, ensuring a smooth and successful transition. We have seen a wonderful feedback from those using it as well as those experiencing our product.
PSQH: Needlestick injuries are among both the most prevalent and the most preventable occupational hazards affecting U.S. healthcare workers. With mass inoculations on the horizon once a COVID-19 vaccine or vaccines are approved, this issue has moved to the forefront.
Needlestick injuries, which fit into the broader category of sharps injuries, can harm healthcare workers by exposing them to blood and other hazardous materials, including infections from hepatitis C, hepatitis B, and HIV, according to the U.S. Centers for Disease Control and Prevention (CDC). Most needlestick injuries are experienced by frontline healthcare workers and can result in emotional impact that is “severe and long-lasting,” according to the CDC.
For the workers who suffer needlestick injuries and the provider organizations that employ them, the consequences can be serious and include the loss of employee time and related costs to investigate the injury, laboratory testing, post-exposure treatment, and replacing or reassigning staff.
While estimates vary, direct and indirect costs of needlestick injuries average more than $3,000 per victim, according to a report from Safe in Common. Further, needlestick and sharps injuries can create “enormous stress” for victims and their families, as testing for bloodborne pathogens can last for months, producing prolonged feelings of anxiety and distress, according to the CDC.
However, needle-free injection technology offers strong potential to alleviate these problems. This technology is designed around a high-pressure, spring-driven, stainless-steel piston and works by using a specially designed syringe to inject liquid medication subcutaneously, intramuscularly, or intradermally via a specialized device. Citing U.S. government statistics, a report in BioMedicine International estimated that 29% of hospital needlestick injuries could be prevented through the adoption of safety-engineered needles or needle-free devices.
Needlestick and sharps injuries: The basics
Sharps injuries are defined as penetrating stab wounds from a needle, scalpel, or other sharp object that may result in exposure to blood or other body fluids. They generally occur as a result of healthcare personnel using sharp equipment in a fast-paced, stressful, and/or understaffed environment. Additionally, sharps injuries sometimes are the result of unsafe practices, including passing sharps hand-to-hand between team members, placing sharps in an overfilled disposal container, failing to use a safer device, or failing to identify a safer alternative, according to the CDC.
Although health experts acknowledge the widespread occurrence of needlestick and sharps injuries, no one really knows how prevalent they are. Figures cited in 2000 by the CDC estimate annual needlestick and other percutaneous injuries to healthcare workers range between 600,000 and 800,000. More recently, BioMedicine International estimated the annual number of needlestick injuries in the United States to be around 384,000.
The reason for the ambiguity is simple: A large amount of needlestick injuries (up to half, according to some estimates) continue to go unreported, meaning that the numbers we have access to are “only the tip of the proverbial iceberg,” the CDC reports. Reasons driving this significant under-reporting may include the time-consuming reporting process, the belief that sharps injuries are minor incidents, and fear of a positive test result for a serious infection. In other cases, workers lack proficiency in needlestick procedures and desire to avoid drawing attention to their errors.
Regardless, the healthcare industry should not be focused on getting an exact count of these incidents. “The occupational health risks associated with contaminated sharps injuries become less about national estimates of overall numbers, but more so about identifying how the injuries that are occurring can be prevented in the future,” the CDC states.
Disposable syringes are the medical devices associated with the highest percentage of sharps injuries, followed by suture needles, scalpel blades, and IV stylets. Injuries from disposable syringes affect nurses more than any other single professional group, according to the CDC.
How needle-free technology can help
Clearly, one of the best ways to reduce the prevalence of needlestick injuries is to reduce healthcare workers’ exposure to needles to the greatest extent possible. Needle-free technology is an obvious solution.
In addition to providing a safer alternative for the administration of vaccines, needle-free injection technology is easy to use and provides a consistent dose of medication compared with the variables of a needle injection, in which proper technique is required such as ideal needle angle and depth of skin penetration.
Further, needle-free injection devices offer a greener, more environmentally friendly option than traditional needles and syringes, as needle-free devices do not require disposal in sharps containers. About 16 billion injections are administered each year across the globe, but in many cases the needles and syringes used for these injections are not disposed of properly, according to the World Health Organization. That leads to risks for healthcare workers and waste handlers, who may be exposed to these sharp objects and any biohazardous materials on them.
While the true scale will likely never be fully appreciated, needlestick and sharps injuries undoubtedly affect hundreds of thousands of U.S. healthcare workers each year, leading to avoidable stress, trauma, and costs. We owe it to them to explore all reasonable alternatives to alleviate these often-preventable incidents. Needle-free injection technology is a great place to start.
Scott E. McFarland, JD, is CEO of IntegriMedical LLC.
Injection-related pain and fear are common adverse reactions in children undergoing vaccination and influence vaccine acceptance. Despite the large body of literature on sources of vaccine non-compliance, there is no estimate of the prevalence of pain and fear as contributing factors. The objective was to estimate the prevalence of injection pain or fear of needles as barriers to childhood (i.e., 0-18 years) vaccination.
Methods: Four databases were searched from inception for relevant English and French articles until August 2021. In addition, the references of recent systematic reviews and all articles included in the review were hand searched. Article screening and data extractions were performed in duplicate. Studies were included if they reported on injection-related pain or fear of needles in children (0-18 years) using a checklist/closed-ended question(s). Results were stratified by respondent (parents or children), type of pediatric population (general or under-vaccinated), and relative importance of barrier (pain or needle fear as primary reason or any reason for under-vaccination). Prevalence rates of pain or needle fear were combined using a random effects model. Quality of included studies was assessed using the Joanna Briggs Institute critical appraisal checklist for prevalence data. Quality across studies was assessed using GRADE.
Results: There were 26 studies with 45 prevalence estimates published between 1995 and 2021. For parent reports (of children) and children self-reported reasons for non-compliance, prevalence rates of pain or needle fear ranged from 5 to 13% in a general population and 8 to 28% in an under-vaccinated population, with a substantial variation in the prevalence estimates. There was no difference between category of respondent or relative importance on pain or needle fear prevalence rate. A regression model demonstrated an overall prevalence rate of pain or needle fear as an obstacle to vaccination of 8% in the general population and 18.3% in the under-vaccinated population. All evidence was very low in quality.
Conclusion: This is the first review to systematically quantify the prevalence and therefore, importance, of pain and needle fear as obstacles to vaccination in children around the world. Pain from injection or fear of needles were demonstrated to be sufficiently prevalent as barriers to vaccination in children to warrant attention. Addressing pain and fear has the potential to significantly improve vaccination acceptance.